% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lewczuk:136413,
      author       = {Lewczuk, Piotr and Popp, Julius and Lelental, Natalia and
                      Kölsch, Heike and Maier, Wolfgang and Jessen, Frank and
                      Kornhuber, Johannes},
      title        = {{C}erebrospinal fluid soluble amyloid-β protein precursor
                      as a potential novel biomarkers of {A}lzheimer's disease.},
      journal      = {Journal of Alzheimer's disease},
      volume       = {28},
      number       = {1},
      issn         = {1875-8908},
      address      = {Amsterdam},
      publisher    = {IOS Press},
      reportid     = {DZNE-2020-02735},
      pages        = {119-125},
      year         = {2012},
      abstract     = {In this report, we confirm our previous findings of
                      increased concentrations of soluble amyloid-β protein
                      precursor (sAβPP) in cerebrospinal fluid (CSF) of patients
                      with Alzheimer's disease (AD) and mild cognitive impairment
                      (MCI) in a large cohort of patients (n = 314), not
                      overlapping with those of our previous study, and we extend
                      our observations by including a control group of
                      participants with normal cognition. In addition, we
                      investigate the effects of age, the APOEε4 genotype, and
                      the blood-CSF barrier function on the concentrations of
                      sAβPPα and sAβPPβ. The study participants were
                      categorized according to clinical-neuropsychological
                      criteria, supported by CSF neurochemical dementia
                      diagnostics (NDD) analyses. sAβPPα concentrations in the
                      AD group (132.0 ± 44.8) were significantly higher than in
                      the control group (105.3 ± 37.3, p < 0.0005) but did not
                      differ from the MCI-AD group (138.5 ± 39.5, p = 0.91). The
                      MCI-AD group differed significantly from the MCI-O (97.3 ±
                      34.3, p < 0.05) group. There was no difference between the
                      control and the MCI-O groups (p = 0.94). Similarly, sAβPPβ
                      concentrations in the AD group (160.2 ± 54.3) were
                      significantly higher than in the control group (129.9 ±
                      44.6, p < 0.005) but did not differ from the MCI-AD group
                      (184.0 ± 56.4, p = 0.20). The MCI-AD group differed
                      significantly from the MCI-O (127.8 ± 46.2, p < 0.05)
                      group. There was no difference between the control and the
                      MCI-O groups (p > 0.99). We observed highly significant
                      correlation of the two sAβPP forms. Age and the CSF-serum
                      albumin ratio were significant albeit weak predictors of the
                      sAβPPα and sAβPPβ concentrations, while carrying the
                      APOEε4 allele did not influenced the levels of the sAβPP
                      forms. Taken together, the results strongly suggest that CSF
                      sAβPP concentrations may be considered as an extension of
                      already available NDD tools.},
      keywords     = {Adult / Aged / Aged, 80 and over / Alzheimer Disease:
                      cerebrospinal fluid / Alzheimer Disease: diagnosis / Amyloid
                      beta-Protein Precursor: cerebrospinal fluid / Apolipoprotein
                      E4: genetics / Biomarkers: cerebrospinal fluid / Cognitive
                      Dysfunction: cerebrospinal fluid / Cognitive Dysfunction:
                      diagnosis / Cohort Studies / Female / Humans / Male / Middle
                      Aged / Amyloid beta-Protein Precursor (NLM Chemicals) /
                      Apolipoprotein E4 (NLM Chemicals) / Biomarkers (NLM
                      Chemicals)},
      cin          = {U Clinical Researchers - Bonn / AG Jessen},
      ddc          = {610},
      cid          = {I:(DE-2719)7000001 / I:(DE-2719)1011102},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:21971403},
      doi          = {10.3233/JAD-2011-110857},
      url          = {https://pub.dzne.de/record/136413},
}